Clinical Outcome Study for Dysferlinopathy

UnknownOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions
DysferlinopathyLGMD2B Now Classified as LGMDR2Miyoshi Myopathy
Trial Locations (16)

28207

Carolinas Medical Center, Neuroscience & Spine Institute, Dept of Neurology, Charlotte

35128

Department of Neurosciences, University of Padova, Padua

41013

Hospital Universitario Virgen del Rocio, IBiS, Neurology Department, Seville

43230

Neuromuscular Center at the Research Institute of Nationwide Children's Hospital, Columbus

63110

Neurology & Pathology, Washington University, School of Medicine in St Louis, St Louis

75013

Institut de Myologie, Paris

944305

Stanford University Medical Center, Palo Alto

Unknown

UC Irvine, Orange

Columbia University Medical Centre, New York

Clinica Davila, Santiago

Rigshospitalet Neuromusculaer Klinik, Copenhagen

Pusan National University Hospital, Busan

Hospital Universitario Donostia, San Sebastián

187-8551

National Center of Neurology and Psychiatry, Kodaira

08041

Hospital Sant Pau, Neurology Department, Barcelona

NE1 3BZ

Institute of Translational and Clinical Research, Newcastle University, International Centre for Life, Newcastle upon Tyne

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Jain Foundation

OTHER

lead

Newcastle-upon-Tyne Hospitals NHS Trust

OTHER

NCT01676077 - Clinical Outcome Study for Dysferlinopathy | Biotech Hunter | Biotech Hunter